

## REMARKS

Upon entry of the proposed amendment, claims 3 to 25 will be pending. Claims 1 and 2 have been canceled.

### 35 U.S.C. 103 (a)


Claims 1, 2, and 11 to 16 and 25 stand rejected as allegedly unpatentable over WO 2001072692, in view of either WO 2001060784 or Silverman, *Organic Chemistry of Drug Design* (1992) pp. 19-23. To expedite prosecution, claims 1 and 2 have been canceled, and claims 11 to 16 and 25 have been amended to depend from claim 3. Accordingly, Applicants respectfully request withdrawal of the rejection.

### Double Patenting

Claims 1 to 16 and 25 stand provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1 to 6 and 16 of co-pending application 10/826,100. Upon indication of allowable subject-matter, Applicants will address the rejection.

Applicants believe that the claims are now in condition for allowance. An early Office Action to that effect is therefore, earnestly solicited.

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

Respectfully submitted,  
  
Maureen S. Gibbons  
Attorney for Applicant  
Reg. No. 44,121  
Phone: 609-252-3453  
Date: May 29, 2007